Strong Growth and Margin Execution Drives Performance in Quarter

Becton, Dickinson and Company (BD) Reports Impressive Q4 Results

FRANKLIN LAKES, N.J. , Nov. 7, 2024 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its fiscal 2024 fourth quarter and full year which ended September 30, 2024.

BD reported strong financial results for Q4 and the full fiscal year 2024, showcasing robust growth and margin execution. In Q4, the company’s revenue reached $5.4 billion, marking a 6.9% increase as reported, 7.4% on a currency-neutral basis, and 6.2% organically. This growth was driven by various factors, including successful product launches and strategic acquisitions.

The Q4 GAAP and adjusted diluted EPS from continuing operations also saw significant growth, with figures of $1.45 and $3.81, representing a 173.6% and 11.4% increase, respectively. For the full fiscal year 2024, BD’s revenue totaled $20.2 billion, up 4.2% as reported and currency-neutral, 4.6% on an adjusted currency-neutral basis, and 5.0% organically. The company’s GAAP and adjusted diluted EPS from continuing operations for FY24 were $5.93 and $13.14, showing growth of 16.3% and 7.6%, respectively.

BD also achieved significant cash flow growth in FY24, with cash from continuing operations increasing by 28.5% to $3.8 billion and Free Cash Flow growing by 47.4% to $3.1 billion. The company’s strong performance and financial outlook led to the issuance of FY25 revenue guidance, projecting further growth in various metrics.

Implications for Individuals

For individuals, BD’s strong financial performance could have positive implications, such as potential job stability and career growth opportunities within the company. Additionally, the company’s continued growth may lead to the development of innovative healthcare products that could improve patient outcomes and quality of life.

Global Impact

On a global scale, BD’s strong growth and margin execution signal a positive outlook for the medical technology industry. The company’s innovative products and solutions have the potential to positively impact healthcare systems worldwide, enhancing the delivery of care and advancing medical knowledge and technology.

Conclusion

In conclusion, BD’s impressive Q4 results and strong performance in FY24 demonstrate the company’s commitment to driving growth and delivering value to its stakeholders. With a solid financial foundation and a positive outlook for the future, BD is poised to continue its trajectory of success in the global medical technology market.